← Evidence library

BIB_321

Reijers ILM, Blank CU et al. PRADO trial 5-year survival + biomarker analysis: neoadjuvant ipilimumab plus nivolumab in stage III macroscopic melanoma. Nat Med April 2025. https://www.nature.com/articles/s41591-025-04158-9. Key numbers: 99 patients; 5-year EFS 71%, RFS 74%, DMFS 79%, OS 86%. ~60% avoided lymph node dissection. Combined high-TMB + high-IFNγ + PD-L1 ≥1% → 100% MPR + 100% 5-year EFS. Validates personalised response-directed surgery in Stage III. [Tasks: 18, 19, 19b] Tier: 1 (Nature Medicine phase 2 LT follow-up) Grade: A Retrieved: 2026-05-15

Evidence grade

A

Tier

1 (Nature Medicine phase 2 LT follow-up)

Cited by tasks

18, 19, 19b

Identifiers

—

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_321/findings.md (research corpus). This page is a short context summary — not individualised medical advice.